Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-38333 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Phospho-SP1 (Thr453) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Melatonin activates ABCA1 via the BiP/NRF1 pathway to suppress high-cholesterol-induced apoptosis of mesenchymal stem cells.
Kim JS, Jung YH, Lee HJ, Chae CW, Choi GE, Lim JR, Kim SY, Lee JE, Han HJ
Stem cell research & therapy 2021 Feb 5;12(1):114
Stem cell research & therapy 2021 Feb 5;12(1):114
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-SP1 pThr453 in extracts from A549 cells using a Phospho-SP1 pThr453 polyclonal antibody (Product # PA5-38333).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Phospho-SP1 pThr453 in HeLa cells using a Phospho-SP1 pThr453 polyclonal antibody (Product # PA5-38333).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-SP1 pThr453 in paraffin-embedded human brain tissue using a Phospho-SP1 pThr453 polyclonal antibody (Product # PA5-38333).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 6 Involvement of melatonin-activated Sp1/miR-597 pathway in BiP suppression. a UCB-MSCs were treated with melatonin (1 muM, 24 h) and total RNAs were extracted. MicroRNA microarray was conducted and the expression levels of microRNAs were analyzed using hierarchical clustering with heatmap. b A cluster of expression-increased microRNAs was selected and their expression levels under high cholesterol and melatonin condition were analyzed by qPCR ( n = 5, *p < 0.05 vs control). c , d miR-597 mimic was transfected to UCB-MSCs for 24 h prior to cholesterol treatment (200 muM, 12 h). The mRNA expressions of HSPA5 and ABCA1 and protein expression levels of BiP and ABCA1 were quantified with qPCR and western blotting ( n = 5, * p < 0.05 vs NT mimic, # p < 0.05 vs NT mimic + cholesterol). e , f MT2 inhibitor 4-P-PDOT (10 muM) was pretreated prior to melatonin treatment (1 muM, 12 h). e The phosphorylation of Sp1 (Thr453) were measured by western blotting ( n = 5, * p < 0.05 vs control, # p < 0.05 vs melatonin). f Immunocytochemistry was conducted with Sp1 (green) specific antibody and DAPI (blue). Scale bar was set as 8 mum (magnification x 1000, n = 5, * p < 0.05 vs control, # p < 0.05 vs melatonin). g Sp1 inhibitor Mithramycin A (5 nM) was pretreated prior to melatonin treatment (1 muM, 12 h), and the change of expression level of miR-597-5p was assessed through qPCR ( n = 5, * p < 0.05 vs control, # p < 0.05 vs melatonin). All images are representative and quantitative data ar